Synergy Pharmaceuticals Inc (SGYP)

4.73
0.05 1.05
NASDAQ : Health Care
Prev Close 4.78
Open 4.80
Day Low/High 4.56 / 4.82
52 Wk Low/High 2.50 / 7.72
Volume 3.53M
Avg Volume 3.02M
Exchange NASDAQ
Shares Outstanding 179.45M
Market Cap 848.78M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

SGYP April 2017 Options Begin Trading

SGYP April 2017 Options Begin Trading

Investors in Synergy Pharmaceuticals Inc saw new options become available today, for the April 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Synergy Pharmaceuticals Reports Second Quarter 2016 Financial Results And Business Update

Synergy Pharmaceuticals Reports Second Quarter 2016 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for...

Bullish Two Hundred Day Moving Average Cross - SGYP

Bullish Two Hundred Day Moving Average Cross - SGYP

In trading on Thursday, shares of Synergy Pharmaceuticals Inc crossed above their 200 day moving average of $4.22, changing hands as high as $4.34 per share. Synergy Pharmaceuticals Inc shares are currently trading up about 0.2% on the day.

Synergy Pharmaceuticals To Present At Canaccord Genuity 36th Annual Growth Conference

Synergy Pharmaceuticals To Present At Canaccord Genuity 36th Annual Growth Conference

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced Marino Garcia, the company's EVP and Chief Strategy Officer, will present a corporate update at the Canaccord Genuity 36 th Annual Growth Conference on Thursday,...

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

Biogen Should Either a Buyer or a Seller Be

Biogen Should Either a Buyer or a Seller Be

The company sans CEO Scangos needs to do some type of deal in the coming months.

Synergy Pharma Offers Lots of Synergies

Synergy Pharma Offers Lots of Synergies

I expect Allergan or another player to bid for SGYP soon.

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

'Mad Money' Lightning Round: Avoid Monsanto Now

'Mad Money' Lightning Round: Avoid Monsanto Now

Cramer says he's frustrated with Synergy Pharmaceuticals' situation.

Jim Cramer's 'Mad Money' Recap: 3 Stocks With Very Different Risks, Rewards

Jim Cramer's 'Mad Money' Recap: 3 Stocks With Very Different Risks, Rewards

The higher the market goes, so, too, will your risks, Cramer says.

SGYP September 16th Options Begin Trading

SGYP September 16th Options Begin Trading

Investors in Synergy Pharmaceuticals Inc saw new options become available today, for the September 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGYP options chain for the new September 16th contracts and identified one put and one call contract of particular interest.

Synergy Pharmaceuticals (SGYP) Stock Slides Despite FDA Updates

Synergy Pharmaceuticals (SGYP) Stock Slides Despite FDA Updates

Synergy Pharmaceuticals (SGYP) announced today that it had reached an FDA milestone on a new drug application.

Synergy Pharmaceuticals Provides Update On Ongoing FDA Review Of Plecanatide CIC NDA And IBS-C Clinical Development Program

Synergy Pharmaceuticals Provides Update On Ongoing FDA Review Of Plecanatide CIC NDA And IBS-C Clinical Development Program

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced it has reached the Food and Drug Administration (FDA) mid-cycle review milestone for the plecanatide new drug application (NDA) in chronic idiopathic constipation...

2 Small Biotech Stocks With Big Milestones

As Brexit turmoil calms down, let's get back to small cap stocks.

'Mad Money' Lightning Round: You're in Good Shape With Charter Communications

'Mad Money' Lightning Round: You're in Good Shape With Charter Communications

Cramer likes Keryx Biopharmaceutical on speculation but is avoiding Synergy Pharmaceuticals.

Jim Cramer's 'Mad Money' Recap: 'Brexit' Is the Dumbest Financial Mistake Ever

Jim Cramer's 'Mad Money' Recap: 'Brexit' Is the Dumbest Financial Mistake Ever

The true cost of British independence from the EU is now becoming apparent, Cramer says.

First Week of SGYP August 19th Options Trading

First Week of SGYP August 19th Options Trading

Investors in Synergy Pharmaceuticals Inc saw new options begin trading this week, for the August 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGYP options chain for the new August 19th contracts and identified one put and one call contract of particular interest.

'Mad Money' Lightning Round: Broadcom Is One of the Best

'Mad Money' Lightning Round: Broadcom Is One of the Best

Cramer likes Celgene despite the biotech sector's problems but is ringing the register on EMC.

Jim Cramer's 'Mad Money' Recap: An Epic Battle of 'Brexit' vs. Oil

Jim Cramer's 'Mad Money' Recap: An Epic Battle of 'Brexit' vs. Oil

Everyone wins in this battle as high-quality stocks become more attractive, Cramer says.

'Mad Money' Lightning Round: Take American Electric Power Over Calpine

'Mad Money' Lightning Round: Take American Electric Power Over Calpine

Cramer thinks United Rentals has bottomed and likes Texas Roadhouse.

Jim Cramer's 'Mad Money' Recap: These Stocks Matter More Than Others

Jim Cramer's 'Mad Money' Recap: These Stocks Matter More Than Others

These stocks will tell you which way the economy is heading, Cramer says.

4 Possible Acquisition Targets in Biotech

These mid-caps would do well by themselves, but could tempt bigger companies.

Synergy Pharmaceuticals Presents New In Vitro Data Showing The PH-Dependent Activity Of Plecanatide Replicates That Of Naturally Occurring GI Peptide Uroguanylin

Synergy Pharmaceuticals Presents New In Vitro Data Showing The PH-Dependent Activity Of Plecanatide Replicates That Of Naturally Occurring GI Peptide Uroguanylin

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today presented new in vitro data at Digestive Disease Week (DDW) showing plecanatide, an investigational compound being evaluated for chronic idiopathic constipation (CIC) and...

Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data In Chronic Idiopathic Constipation At Digestive Disease Week

Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data In Chronic Idiopathic Constipation At Digestive Disease Week

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, the company's first uroguanylin analog,...

Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data In Chronic Idiopathic Constipation At Digestive Disease Week

Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data In Chronic Idiopathic Constipation At Digestive Disease Week

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional data from two pivotal phase 3 clinical trials (Study-00 and Study-03) evaluating the efficacy and safety of plecanatide, a once-daily oral tablet, in...

Synergy Pharmaceuticals To Present New Plecanatide Data At Digestive Disease Week 2016

Synergy Pharmaceuticals To Present New Plecanatide Data At Digestive Disease Week 2016

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present data on plecanatide, the first uroguanylin analog being evaluated for the treatment of chronic idiopathic constipation (CIC) and...